Description

Denotect 120 mg contains Denosumab, a fully human monoclonal antibody that targets and inhibits RANK ligand (RANKL), a key mediator of osteoclast formation and activity. It is administered as a subcutaneous injection under medical supervision.

🔬 Mechanism of Action Denotect 120 mg

Denosumab binds to RANKL and prevents it from activating its receptor (RANK) on osteoclasts. As a result:

• Osteoclast formation is reduced
• Bone resorption is inhibited
• Bone strength is preserved
• Risk of fractures and skeletal complications decreases

This targeted action makes it highly effective in managing cancer-related bone disease.

💊 Indications

Denotect 120 mg is indicated for:

• Prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors
• Multiple Myeloma with bone involvement
• Giant Cell Tumor of Bone (unresectable or when surgery may cause severe morbidity)
• Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy

📌 Key Features of Denotect 120 mg

• Strength: 120 mg
• Dosage Form of Denotect 120 mg: Subcutaneous injection
• Therapeutic Class: RANKL Inhibitor / Monoclonal Antibody
• Administration: Given as a subcutaneous injection, typically every 4 weeks
• Monitoring: Serum calcium levels and kidney function monitoring recommended

⚕️ Benefits of Denosumab

• Reduces risk of fractures and skeletal complications
• Preserves bone density
• Effective alternative to bisphosphonates
• Convenient subcutaneous administration

⚠️ Precautions

• Risk of hypocalcemia — calcium and vitamin D supplementation recommended
• Rare risk of osteonecrosis of the jaw (ONJ); dental evaluation advised before treatment
• Possible infections and skin reactions
• Use strictly under oncologist supervision

Denotect 120 mg (Denosumab Injection) is an advanced bone-targeted therapy that helps protect bone integrity and reduce complications in cancer patients with bone involvement, supporting improved quality of life under specialized medical care.